Navigation Links
Lilly announces Tapiero retiring; Zulueta promoted to senior vice president and president of Emerging Markets
Date:10/24/2013

INDIANAPOLIS, Oct. 24, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Alfonso "Chito" Zulueta will be promoted to senior vice president and president of the Emerging Markets business effective Jan. 1, 2014. Zulueta will replace Jacques Tapiero who will retire Jan. 31, 2014, after 31 years of service to the company.

Zulueta has been president and general manager of Lilly Japan since 2008. In his new role, he will lead the company's efforts in many of the world's fastest-growing markets in Asia, Latin America, Middle East and Africa, plus Russia and Turkey.  Zulueta will report to John Lechleiter, Ph.D., chairman, president, and CEO, and will serve on the company's executive committee.

Tapiero joined Lilly in 1983 as a financial analyst. He became president of Emerging Markets in 2009. Prior to that, he had served as president of the intercontinental region for Lilly, which comprised offices in Asia, Australia, Africa, the Middle East, Canada, Latin America, and Russia, and had been general manager of several affiliates.

"Jacques Tapiero has made extraordinary contributions to our company throughout his 31-year career with Lilly, culminating in 2009 with his appointment to lead our important Emerging Markets business," Lechleiter said. "Jacques' leadership has been characterized by strong operational skills and a keen focus on the development of Lilly people around the world. Jacques has been an exemplar of our values of integrity, excellence, and respect for people."

Born in the Philippines, Zulueta received a bachelor's degree in economics from De La Salle University in the Philippines in 1982 and an MBA from the University of Virginia in 1987. In his 25 year career with Lilly, Zulueta has held several sales and marketing leadership positions in the United States before becoming general manager for the Philippines affiliate in 1995. He served as president of Asian operations prior to being promoted in 2008 to his current role as president and general manager of Lilly Japan, the company's second largest market and affiliate behind only the U.S.

"I am delighted to welcome Chito Zulueta to the company's top management team," said Lechleiter. "Chito's previous Lilly assignments have provided him with the global experience necessary for his new role as head of our Emerging Markets business. Chito's business savvy, his insights into diverse markets and cultures, and his passion for the patients whom we serve have enabled him to deliver outstanding results throughout his career. He is the ideal candidate to assume this important position."

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers — through medicines and information — for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

Refer to: (317) 612-4974; chaversjm@lilly.comJanice Chavers
(317) 997-1481 amy.sousa@lilly.comAmy Sousa

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Reports Third-Quarter 2013 Results
2. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
3. Lilly Declares Fourth-Quarter 2013 Dividend
4. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
5. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
6. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
7. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
8. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
9. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
10. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
11. Dr. Marschall S. Runge Elected to Lilly Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Israel and TAMPA, Fla. , Feb. ... emerging medical device company focused on developing cerebral ... applauds the members of the FDA,s Circulatory System ... their acknowledgement of the need for cerebral protection ... "The statements shared by this FDA panel ...
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
(Date:2/27/2017)... 27, 2017 A recent research report published ... market alone is expected to reach a value of $55.8 billion ... along with 28 states have legalized marijuana for medical uses. In ... Florida , North Dakota , ... to use the drug in medical applications such as chemotherapies and ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... It’s no secret that aging ... to a host of health issues, including urinary incontinence. However, results published in ... that good overall muscle strength in older women, particularly in the abdominal and ...
(Date:2/27/2017)... ... , ... The threat of nuclear warfare has long plagued this world. In ... underground testing of nuclear weapons. Years later, when her co-workers began dying, Dot started ... Nuclear Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... POUGHKEEPSIE, N. ... ) has disclosed that despite scientific studies, the Center for Disease Control ( CDC ... Lyme disease . Kenneth B. Liegner, M.D. has compiled into a single volume ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top ... and genders. And the need for advanced services is growing. , Project WE ... care program, in collaboration with their non-profit partners in their fight against cancer and ...
(Date:2/26/2017)... New York, New York (PRWEB) , ... February ... ... of luxury baby products for wholesale distribution in North America, today announced it ... established online sites. The company, which prides itself on crafting quality and unique ...
Breaking Medicine News(10 mins):